Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 19, Issue 3, Pages 986-989Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2008.11.078
Keywords
Chagas' disease; Trypanosoma cruzi; Quinolones; Antitrypanosomal; Antibacterial activity
Categories
Funding
- United Nations Development Program
- World Health Organization
- Special Program for Research and Training in Tropical Diseases
Ask authors/readers for more resources
Chagas' disease, caused by Trypanosoma cruzi (T. cruzi), is one of the most serious parasitic diseases in Latin America. The currently available chemotherapy, based on nifurtimox or benznidazole, is unsatisfactory due to the limited efficacy in the prevalent chronic stage of the disease and toxic side effects. In order to address these deficiencies, a series of quinolones based novel molecules have been synthesized and evaluated as potential antitrypanosomal agents. The most active analogue 10 inhibited T. cruzi with an IC50 of 1.3 mu g/mL. The results of this study have implications in the development of novel quinolone's antitrypanosomal agents. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available